Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02435849
Registration number
NCT02435849
Ethics application status
Date submitted
16/04/2015
Date registered
6/05/2015
Date last updated
13/02/2024
Titles & IDs
Public title
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Query!
Scientific title
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Query!
Secondary ID [1]
0
0
2013-003205-25
Query!
Secondary ID [2]
0
0
CCTL019B2202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ELIANA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
B-cell Acute Lymphoblastic Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - CTL019
Experimental: Single dose of CTL019 - Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
Other interventions: CTL019
Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10^6 tisagenlecleucel per kg body weight (for patients = 50 kg) or 1.0 to 2.5x10^8 tisagenlecleucel (for patients >50 kg).
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Overall Remission Rate (ORR) as Determined by Independent Review Committee (IRC) Assessment.
Query!
Assessment method [1]
0
0
Evaluating the efficacy of tisagenlecleucel therapy from all manufacturing facilities as measured by overall remission rate (ORR) during the 3 months after tisagenlecleucel administration. ORR included complete response (CR) and CR with incomplete blood count recovery (CRi) as determined by an Independent Review Committee assessment. Per response criteria defined by National Comprehensive Cancer Network (NCCN), American Society of Hematology (ASH) and International Working Group (IWG) guidelines.
CR is defined as:
Bone marrow <5% blasts, Peripheral blood: Neutrophils >1.0 x 10^9/L, and Platelets >100 x 10^9/L and Circulating blasts <1% and No evidence of extramedullary disease, at least 7 days transfusion independency.
CRi is defined as all the prior criteria being met, except that the following exists: Neutrophils =1.0 x 10^9/L, and/or Platelets =100 x 10^9/L, and/or Platelet and/or neutrophil transfusions =7 days before the date of the peripheral blood sample for disease assessment.
Query!
Timepoint [1]
0
0
during the 3 months after tisagenlecleucel administration
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Overall Remission Rate (ORR) as Per IRC From US Manufacturing Facilities in the Main Cohort Only (Key Secondary)
Query!
Assessment method [1]
0
0
These are the percentage of participants with ORR who achieved overall remission rate which includes complete response (CR) and CR with incomplete blood count recovery (CRi) as determined by IRC assessment after having been infused with tisagenlecleucel from US manufacturing facilities.
Query!
Timepoint [1]
0
0
3 months after tisagenlecleucel administration
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Best Overall Response (BOR) of CR or CRi With Minimal Residue Disease (MRD) Negative Bone Marrow From US Manufacturing Facility as Per IRC in the Main Cohort Only (Key Secondary)
Query!
Assessment method [2]
0
0
These are the percentage of participants who achieved Best Overall Response (BOR) of complete response (CR) or complete response with incomplete blood count recovery (CRi) with an MRD-negative bone marrow by central analysis using flow cytometry among participants who received tisagenlecleucel from US manufacturing facilities only, by IRC assessment.
Query!
Timepoint [2]
0
0
3 months after tisagenlecleucel administration
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Best Overall Response (BOR) of CR or CRi With MRD Negative Bone Marrow by Flow Cytometry From All Manufacturing Facilities as Per IRC in the Main Cohort Only (Key Secondary)
Query!
Assessment method [3]
0
0
These are the percentage of participants who achieved Best Overall Response (BOR) of CR or CRi with an MRD-negative bone marrow by central analysis using flow cytometry among participants who received tisagenlecleucel from all manufacturing facilities by IRC assessment. MRD negative = MRD% < 0.01%
Query!
Timepoint [3]
0
0
3 months after tisagenlecleucel administration
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Achieved CR or CRi Without Hematopoietic Stem Cell Transplantation (HSCT)
Query!
Assessment method [4]
0
0
These are the participants who achieved CR or CRi without HSCT between tisagenlecleucel (CTL019) infusion and Month 6 response assessment.
Query!
Timepoint [4]
0
0
6 months after tisagenlecleucel administration
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Achieved CR or CRi and Then Proceeded to Hematopoietic Stem Cell Transplantation (HSCT) While in Remission Prior to Month 6 Resoonse
Query!
Assessment method [5]
0
0
These are the participants who achieved CR or CRi and then proceeded to HSCT while in remission prior to Month 6 response assessment
Query!
Timepoint [5]
0
0
6 months
Query!
Secondary outcome [6]
0
0
Number of Participants Who Proceeded to Hematopoietic Stem Cell Transplantation (HSCT) After Tisagenlecleucel (CTL019) Infusion
Query!
Assessment method [6]
0
0
These are the participants who achieved CR or CRi and then proceeded to SCT after being infused by tisagenlecleucel.
Query!
Timepoint [6]
0
0
up to 6 months
Query!
Secondary outcome [7]
0
0
Duration of Remission (DOR)
Query!
Assessment method [7]
0
0
DOR is the time from achievement of CR or CRi at any time post-infusion, whichever occurs first, to relapse or death.
Query!
Timepoint [7]
0
0
60 months
Query!
Secondary outcome [8]
0
0
Site of Involvement of Subsequent Relapse
Query!
Assessment method [8]
0
0
Anatomical location of relapse in participants who achieved prior CR/CRi subsequent to tisagenlecleucel infusion.
Query!
Timepoint [8]
0
0
60 months
Query!
Secondary outcome [9]
0
0
Relapse-free Survival Per IRC Assessment
Query!
Assessment method [9]
0
0
RFS is the time from achievement of CR or CRi at any time post-infusion, whichever occurs first, to relapse or death due to any cause during CR or CRi.
Query!
Timepoint [9]
0
0
60 months
Query!
Secondary outcome [10]
0
0
Event-free Survival Per IRC Assessment
Query!
Assessment method [10]
0
0
EFS is the time from date of tisagenlecleucel infusion to the earliest of death, relapse or treatment failure.
Query!
Timepoint [10]
0
0
60 months
Query!
Secondary outcome [11]
0
0
Overall Survival (OS)
Query!
Assessment method [11]
0
0
OS, is the time from date of tisagenlecleucel infusion to the date of death due to any reason.
Query!
Timepoint [11]
0
0
60 months
Query!
Secondary outcome [12]
0
0
Percentage of Participants Attaining CR or CRi at Day 28 +/- 4 Days Post Tisagenlecleucel (CTL019) Infusion by IRC Assessment
Query!
Assessment method [12]
0
0
These are participants who had a day 28 response (CR or CRi response) by IRC assessment.
Query!
Timepoint [12]
0
0
1 month
Query!
Secondary outcome [13]
0
0
Response as a Function of Baseline Tumor Burden (Tumor Load) in Main Cohort Only
Query!
Assessment method [13]
0
0
Percentage of participants who achieved BOR of CR or CRi by flow cytometry as a function of baseline bone marrow tumor burden.
Query!
Timepoint [13]
0
0
3 months
Query!
Secondary outcome [14]
0
0
Bone Marrow MRD Status by Flow Cytometry Per IRC Assessment
Query!
Assessment method [14]
0
0
Percentage of participants who achieved CR or CRi response with bone marrow MRD negative (MRD < 0.01%) after tisagenlecleucel infusion by flow cytometry.
Query!
Timepoint [14]
0
0
28 days
Query!
Secondary outcome [15]
0
0
Tisagenlecleucel Transgene Levels by qPCR in Peripheral Blood by Day 28 Response by Independent Review Committee (IRC) Assessment
Query!
Assessment method [15]
0
0
This is the summary of cellular kinetic concentrations for Tisagenlecleucel (CTL019) transgene levels by qPCR in peripheral blood.
Query!
Timepoint [15]
0
0
Month 60
Query!
Secondary outcome [16]
0
0
Tisagenlecleucel Transgene Levels by qPCR in Bone Marrow by Day 28 Response by IRC Assessment
Query!
Assessment method [16]
0
0
This is the summary of cellular kinetic concentrations for Tisagenlecleucel (CTL019) transgene levels by qPCR in bone marrow.
Query!
Timepoint [16]
0
0
Month 6
Query!
Secondary outcome [17]
0
0
Expression of Tisagenlecleucel (CTL019) Detected by Flow Cytometry in Peripheral Blood by Day 28 Disease Response Per IRC Assessment
Query!
Assessment method [17]
0
0
This is the summary cellular kinetic concentrations for CTL019 by flow cytometry in peripheral blood. It evaluated the persistence of transduced CTL019 cells post-infusion. Observation was up to Month 60 for peripheral blood.
Query!
Timepoint [17]
0
0
Month 60
Query!
Secondary outcome [18]
0
0
Expression of Tisagenlecleucel (CTL019) Detected by Flow Cytometry in Bone Marrow by Day 28 Response by IRC Assessment
Query!
Assessment method [18]
0
0
This is the summary cellular kinetic concentrations for CTL019 by flow cytometry. It evaluated the persistence of transduced CTL019 cells post-infusion. Observation was up to Month 6 for bone marrow.
Query!
Timepoint [18]
0
0
Month 6
Query!
Secondary outcome [19]
0
0
Pharmacokinetics (PK) Parameter: Cmax by qPCR in Peripheral Blood, by Day 28 Disease Response by IRC
Query!
Assessment method [19]
0
0
Cmax is the maximum (peak) observed in peripheral blood drug concentration after single dose administration reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment. The reported Cmax is the summary of maximum level observed based on the data from each patient and based on all the data that's been collected for up to 60 months in a patient.
Query!
Timepoint [19]
0
0
60 months
Query!
Secondary outcome [20]
0
0
Pharmacokinetics (PK) Parameter: Tmax by qPCR in Peripheral Blood, by Day 28 Disease Response by IRC
Query!
Assessment method [20]
0
0
Tmax is the time to reach maximum (peak) peripheral blood drug concentration after single dose administration (days)", reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment. The time frame of 60 months refers to the duration for which the data were reviewed to identify the time of Cmax for this measure.
Query!
Timepoint [20]
0
0
60 months
Query!
Secondary outcome [21]
0
0
Pharmacokinetics (PK) Parameter: AUCs by qPCR in Peripheral Blood, by Day 28 Disease Response by IRC
Query!
Assessment method [21]
0
0
AUC (area under curve) from day of infusion to day 28 or other disease assessment days, in peripheral blood (% or copies/µg x days), reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas 84 days is the actual timepoint for endpoint assessment. : AUC is defined based on the time window i.e., AUC from 0 to 84 days after infusion. Therefore, the time frame specifies the maximum time for up to which the data are used for estimation of AUC (84 days for AUC84d).
Query!
Timepoint [21]
0
0
0 to 84 days after infusion
Query!
Secondary outcome [22]
0
0
Persistence of Tisagenlecleucel (CTL019) in Blood, Bone Marrow and CSF if Available, by qPCR, by Day 28 Response by IRC
Query!
Assessment method [22]
0
0
Persistence is defined as the time corresponding to last quantifiable transgene level in peripheral blood (Tlast), reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment.
Query!
Timepoint [22]
0
0
60 months
Query!
Secondary outcome [23]
0
0
Prevalence and Incidence of Immunogenicity to Tisagenlecleucel (CTL019)
Query!
Assessment method [23]
0
0
This is defined as the percentage of participants who tested positive for anti-mCAR19 antibodies at any time post-baseline, reported by CR/CRi, no response (NR), Unknown and by All participants. .
Query!
Timepoint [23]
0
0
At any time post-baseline, up to a max. of 60 months
Query!
Secondary outcome [24]
0
0
Effects of CTL019 Therapy on Patient Reported Outcomes as Measured by PedsQL Questionnaire
Query!
Assessment method [24]
0
0
The PedsQL questionnaire was for patients = 8-years-old who achieved BOR as CR or CRi within 3 months and the questionnaire was on emotional, social, school, physical, and psychosocial health. Scores are transformed on a scale from 0 to 100, with the sum of all the items over the number of items answered on all the scales. The total scale score is the averaged value of scores of subscales, which means for each subscale and the total scale, the allowed ranges are 0-100. Higher scores on the PedsQL questionnaire for these subscales indicate consistent improvement of health-related quality of life (HRQol).
Query!
Timepoint [24]
0
0
Month 3, M6, M12, M24, M60
Query!
Secondary outcome [25]
0
0
Effects of CTL019 Therapy on Patient Reported Outcomes as Measured by EQ-5D Questionnaire
Query!
Assessment method [25]
0
0
Results from the EQ-5D questionnaire is for number of participants who achieved CR or CRi at month 60. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain & discomfort, anxiety & depression. Respondents are asked to choose the statement in each dimension that best describes their health status on the day surveyed. Their responses are coded as a number (1, 2, or 3) that corresponds to the respective level of severity: 1 indicates no problems, 2 some problems, and 3 severe problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The scores are then normalized to a value from 0-100 where higher scores = better HRQOL & fewer problems or symptoms.
Query!
Timepoint [25]
0
0
Month 60
Query!
Secondary outcome [26]
0
0
Develop a Score Utilizing Clinical and Biomarker Data and Assess Its Ability for Early Prediction of Cytokine Release Syndrome (CRS)
Query!
Assessment method [26]
0
0
Derivation of a score to predict cytokine release syndrome. Considering the complexity and challenges of building a scoring system based on limited data from the trial, this analysis was not performed.
Query!
Timepoint [26]
0
0
3 months
Query!
Secondary outcome [27]
0
0
Frequent Monitoring of Concentrations of Soluble Immune Factors in Blood (C Reactive Protein & Ferritin)
Query!
Assessment method [27]
0
0
Profile of soluble immune factors of key inflammatory markers and cytokine parameters in blood by maximum CRS grade that may be key to cytokine release syndrome (CRS).
Query!
Timepoint [27]
0
0
Maximum post-baseline (approx. 60 months)
Query!
Secondary outcome [28]
0
0
Frequent Monitoring of Concentrations of Soluble Immune Factors in Blood (All Other Inflammatory Markers)
Query!
Assessment method [28]
0
0
Profile of soluble immune factors of key inflammatory markers and cytokine parameters in blood by maximum CRS grade that may be key to cytokine release syndrome (CRS).
Query!
Timepoint [28]
0
0
Maximum post-baseline (approx. 60 months)
Query!
Secondary outcome [29]
0
0
Percentage Change From Baseline of Levels of B and T Cells (Blood and Bone Marrow) Prior to and Following CTL019 Infusion
Query!
Assessment method [29]
0
0
Levels of B and T cells (blood and bone marrow) prior to and following CTL019 infusion for safety monitoring
Query!
Timepoint [29]
0
0
Month 3, Month 12, Maximum post-baseline (approx. 60 months)
Query!
Secondary outcome [30]
0
0
Percentage of Participants With Overall Remission Rate (ORR) - From Fraunhofer Institute Manufacturing Facility
Query!
Assessment method [30]
0
0
These are the percentage of participants with ORR who achieved overall remission rate which includes complete response (CR) and CR with incomplete blood count recovery (CRi) as determined by IRC assessment after having been infused with tisagenlecleucel from Fraunhofer Institute manufacturing facility.
Query!
Timepoint [30]
0
0
60 months
Query!
Secondary outcome [31]
0
0
Percentage of Participants With Best Overall Response (BOR) of CR or CRi With Minimal Residue Disease (MRD) Negative Bone Marrow From Fraunhofer Institute Manufacturing Facility as Per IRC
Query!
Assessment method [31]
0
0
These are the percentage of participants who achieved Best Overall Response (BOR) of CR or CRi with an MRD-negative bone marrow by central analysis using flow cytometry among participants who received tisagenlecleucel from Fraunhofer Institute manufacturing facilities only, by IRC assessment.
Query!
Timepoint [31]
0
0
3 months
Query!
Secondary outcome [32]
0
0
Tisagenlecleucel Transgene Levels by qPCR in Peripheral Blood - Tisagenlecleucel Manufactured From Fraunhofer Institute
Query!
Assessment method [32]
0
0
This is the summary of cellular kinetic concentrations for Tisagenlecleucel (CTL019) transgene levels by qPCR, by disease response in blood by IRC assessment. The assessment of the efficacy, safety and in vivo cellular pharmacokinetics are for patients infused with tisagenlecleucel manufactured by Fraunhofer Institute.
Query!
Timepoint [32]
0
0
Month 60
Query!
Secondary outcome [33]
0
0
Tisagenlecleucel Transgene Levels by qPCR in Bone Marrow - Tisagenlecleucel Manufactured From Fraunhofer Institute
Query!
Assessment method [33]
0
0
This is the summary of cellular kinetic concentrations for Tisagenlecleucel (CTL019) transgene levels by qPCR, by disease response in bone marrow by IRC assessment. The assessment of the efficacy, safety and in vivo cellular pharmacokinetics are for patients infused with tisagenlecleucel manufactured by Fraunhofer Institute.
Query!
Timepoint [33]
0
0
Month 3
Query!
Eligibility
Key inclusion criteria
1. Relapsed or refractory pediatric B-cell ALL
2. Adequate organ function
3. For relapsed patients, documentation of CD19 tumor expression within 3 months of study
entry.
4. Bone marrow with = 5% lymphoblasts by morphologic assessment at screening.
5. Life expectancy > 12 weeks.
6. Karnofsky (age =16 years) or Lansky (age < 16 years) performance status = 50 at
screening
7. Signed written informed consent and assent forms
8. Must meet the institutional criteria to undergo leukapheresis or have an acceptable,
store leukapheresis product
9. Must have an apheresis product of non-mobilized cells received and accepted by the
manufacturing site.
10. Cohort 1 only:
1. First relapse AND hypodiploid cytogenetics OR
2. First relapse AND t(17;19) with defined TCF3-HLF fusion OR
3. First relapse with any cytogenetics provided the relapse occurred = 36 months of
initial diagnosis AND MRD at end of reinduction therapy is =0.01% by flow
cytometry (local assessment)
Query!
Minimum age
No limit
Query!
Query!
Maximum age
25
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
1. Isolated extra-medullary disease relapse
2. Patients with concomitant genetic syndrome: such as patients with Fanconi anemia,
Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome.
Patients with Down Syndrome will not be excluded.
3. Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL,
leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL,
with FAB L3 morphology and /or a MYC translocation)
4. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative
intent and with no evidence of active disease
5. Treatment with any prior gene therapy product
6. Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19
therapy
7. Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening),
or any uncontrolled infection at screening
8. Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening
9. Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD).
10. Active CNS involvement by malignancy, defined by CNS-3 per NCCN guidelines.
11. Patient has an investigational medicinal product within the last 30 days prior to
screening.
12. Pregnant or nursing (lactating) women.
13. Women of child-bearing potential, defined as physiologically capable of becoming
pregnant, unless they agree to use highly effective methods of contraception for at
least 12 months after the CTL019 infusion and after CAR T-cells are no longer present
by qPCR on two consecutive tests
14. Sexually active males must use a condom during intercourse at least 12 months after
the CTL019 infusion after CAR T-cells are no longer present by qPCR on two consecutive
tests
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/04/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/11/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
80
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Utah
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Wien
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Gent
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Cedex 10
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Paris
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Frankfurt
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
MB
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Kyoto
Query!
Country [20]
0
0
Norway
Query!
State/province [20]
0
0
Oslo
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Barcelona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and
safety of CTL019 in pediatric patients with r/r B-cell ALL.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02435849
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02435849
Download to PDF